XML 36 R25.htm IDEA: XBRL DOCUMENT
v3.21.2

License, Clinical Trial and Sponsored Research Agreements (City of Hope - Licenses) (Narrative) (Details) € in Millions |  |  |  |  |  | 1 Months Ended | 3 Months Ended | 9 Months Ended
--- | --- | --- | --- | --- | --- | --- | --- | ---
Sep. 08, 2021 USD ($) | Apr. 01, 2021 USD ($) Milestone | Aug. 23, 2019 USD ($) Milestone | Jul. 03, 2017 USD ($) Milestone | May 31, 2017 USD ($) Milestone | Oct. 31, 2020 USD ($) Milestone | Oct. 31, 2020 EUR (€) Milestone | May 31, 2017 USD ($) Milestone | Feb. 28, 2017 USD ($) Milestone | Sep. 30, 2021 USD ($) | Sep. 30, 2020 USD ($) | Sep. 30, 2021 USD ($) | Sep. 30, 2020 USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development - licenses acquired |  |  |  |  |  |  |  |  |  | $ 630,000 | $ 287,000 | $ 1,630,000 | $ 1,837,000
License Agreements [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development - licenses acquired |  |  |  |  |  |  |  |  |  | 630,000 | 287,000 | 1,630,000 | 1,837,000
License Agreements [Member] | Leiden University Medical Centre [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront fees paid | $ 400,000 |  |  |  |  |  |  |  |  |  |  |  |
Research and development - licenses acquired |  |  |  |  |  |  |  |  |  | 350,000 | 0 | 350,000 | 0
License Agreements [Member] | Leiden University Medical Centre [Member] | Achievement of Certain Milestones [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Milestones payable | $ 31,000,000 |  |  |  |  |  |  |  |  |  |  |  |
License Agreements [Member] | CD123 (MB-102) [Member] | City of Hope National Medical Center ("COH") [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Number of milestones | Milestone |  |  |  |  |  |  |  |  | 8 |  |  |  |
Milestones payable |  |  |  |  |  |  |  |  | $ 14,500,000 |  |  |  |
Research and development - licenses acquired |  |  |  |  |  |  |  |  |  | 0 | 0 | 250,000 | 334,000
License Agreements [Member] | IL13Ra2 (MB-101) [Member] | City of Hope National Medical Center ("COH") [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Number of milestones | Milestone |  |  |  |  |  |  |  |  | 8 |  |  |  |
Milestones payable |  |  |  |  |  |  |  |  | $ 14,500,000 |  |  |  |
Research and development - licenses acquired |  |  |  |  |  |  |  |  |  | 0 | 0 | 0 | 333,000
License Agreements [Member] | Spacer [Member] | City of Hope National Medical Center ("COH") [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development - licenses acquired |  |  |  |  |  |  |  |  |  | 0 | 0 | 0 | 333,000
License Agreements [Member] | PSCA (MB-105) [Member] | City of Hope National Medical Center ("COH") [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Annual maintenance fee payable |  |  |  |  |  |  |  | $ 50,000 |  |  |  |  |
Upfront fees paid |  |  |  |  |  |  |  | $ 300,000 |  |  |  |  |
Number of milestones | Milestone |  |  |  |  |  |  |  | 10 |  |  |  |  |
Milestones payable |  |  |  |  |  |  |  | $ 14,900,000 |  |  |  |  |
Research and development - licenses acquired |  |  |  |  |  |  |  |  |  | 250,000 | 0 | 250,000 | 0
License Agreements [Member] | XSCID (MB-107 and MB-207) [Member] | CSL Behring (Calimmune) [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront fees paid |  |  | $ 200,000 |  |  |  |  |  |  |  |  |  |
Number of milestones | Milestone |  |  | 3 |  |  |  |  |  |  |  |  |  |
Milestones payable |  |  | $ 1,200,000 |  |  |  |  |  |  |  |  |  |
Research and development - licenses acquired |  |  |  |  |  |  |  |  |  | 30,000 | 170,000 | 30,000 | 170,000
License Agreements [Member] | HER2 (MB 103) [Member] | City of Hope National Medical Center ("COH") [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Annual maintenance fee payable |  |  |  |  | $ 50,000 |  |  |  |  |  |  |  |
Upfront fees paid |  |  |  |  | $ 600,000 |  |  |  |  |  |  |  |
Number of milestones | Milestone |  |  |  |  | 10 |  |  |  |  |  |  |  |
Milestones payable |  |  |  |  | $ 14,900,000 |  |  |  |  |  |  |  |
Research and development - licenses acquired |  |  |  |  |  |  |  |  |  | 0 | 0 | 0 | 250,000
License Agreements [Member] | CD20 (MB-106) [Member] | Fred Hutchinson Cancer Research Center [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Annual maintenance fee payable |  |  |  | $ 50,000 |  |  |  |  |  |  |  |  |
Upfront fees paid |  |  |  | $ 300,000 |  |  |  |  |  |  |  |  |
Number of milestones | Milestone |  |  |  | 11 |  |  |  |  |  |  |  |  |
Milestones payable |  |  |  | $ 39,100,000 |  |  |  |  |  |  |  |  |
Research and development - licenses acquired |  |  |  |  |  |  |  |  |  | 0 | 0 | 0 | 300,000
License Agreements [Member] | Car T Technology [Member] | Mayo Clinic [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Annual maintenance fee payable |  | $ 25,000 |  |  |  |  |  |  |  |  |  |  |
Upfront fees paid |  | $ 800,000 |  |  |  |  |  |  |  |  |  |  |
Number of milestones | Milestone |  | 11 |  |  |  |  |  |  |  |  |  |  |
Milestones payable |  | $ 92,600,000 |  |  |  |  |  |  |  |  |  |  |
Research and development - licenses acquired |  |  |  |  |  |  |  |  |  | 0 | 0 | 750,000 | 0
License Agreements [Member] | LentiBOOST Technology [Member] | SIRION Biotech [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront fees paid |  |  |  |  |  | $ 100,000 | € 0.1 |  |  |  |  |  |
Research and development - licenses acquired |  |  |  |  |  |  |  |  |  | $ 0 | $ 117,000 | $ 0 | $ 117,000
License Agreements [Member] | LentiBOOST Technology [Member] | SIRION Biotech [Member] | Achievement of Certain Milestones [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Number of milestones | Milestone |  |  |  |  |  | 5 | 5 |  |  |  |  |  |
Milestones payable |  |  |  |  |  | $ 5,400,000 | € 4.7 |  |  |  |  |  |
License Agreements [Member] | LentiBOOST Technology [Member] | SIRION Biotech [Member] | Worldwide net Sales of Licensed Products [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Number of milestones | Milestone |  |  |  |  |  | 3 | 3 |  |  |  |  |  |
Milestones payable |  |  |  |  |  | $ 4,000,000.0 | € 3.5 |  |  |  |  |  |

X
- Definition The amount of annual maintenance fee payable under the arrangement. + References No definition available. + Details
Name: | mbio_AnnualMaintenanceFeePayable
Namespace Prefix: | mbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of milestones payable under the arrangement. + References No definition available. + Details
Name: | mbio_MilestonesPayableUnderArrangement
Namespace Prefix: | mbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The number of milestones measured under the arrangement. + References No definition available. + Details
Name: | mbio_NumberOfMilestonesMeasured
Namespace Prefix: | mbio_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Payment of Upfront Fees + References No definition available. + Details
Name: | mbio_PaymentOfUpfrontFees
Namespace Prefix: | mbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275 + Details
Name: | us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=mbio_LicenseAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=mbio_LeidenUniversityMedicalCentreMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=mbio_AchievementOfCertainMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mbio_Cd123ProductOrProcessMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=mbio_CityOfHopeNationalMedicalCenterCohMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mbio_Il13r2ProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mbio_SpacerTechnologyProductOrProcessMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mbio_PscaProductOrProcessMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mbio_XscidMb107AndMb207ProductOrProcessMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=mbio_CalimmuneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mbio_Her2ProductOrProcessMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mbio_Cd20TechnologyProductOrProcessMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=mbio_FredHutchinsonCancerResearchCenterMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mbio_CarTTechnologyProductOrProcessMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=mbio_MayoClinicMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mbio_LentiboostTechnologyProductOrProcessMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=mbio_SirionBiotechMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=mbio_WorldwideNetSalesOfLicensedProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |